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Previously, we have demonstrated that Interleukin-4 (IL-4)
receptor alpha (IL-4Ra) is overexpressed in bladder cancer
biopsy specimens and its expression level correlates with
the grade and stage of disease. Based on these observa-
tions, it is proposed that IL-4Ra is a prognostic biomarker
for bladder cancer. To target IL-4Ra, we have developed a
recombinant chimeric fusion immunotoxin, which consists
of circularly permuted IL-4 and truncated Pseudomonas
exotoxin (IL-4-PE) [1]. Here we demonstrate that IL-4-PE
is highly cytotoxic to eight bladder cancer cell lines in
vitro. The cytotoxicity by IL-4-PE was mediated in a con-
centration dependent manner and this cytotoxicity was
receptor specific as excess IL-4 inhibited cytotoxicity
mediated by IL-4-PE. IL-4-PE immunotoxin also killed
bladder cancer colonies in a concentration dependent
manner in a clonogenic assay. We developed three subcu-
taneous tumor models in athymic nude mice using three
different bladder cancer cell lines (UM-UC-3, SW780 and
5637), which are sensitive to IL-4-PE at a variable degree.
These mice were treated with 50 μg/kg, 100 μg/kg of IL-4-
PE immunotoxin or vehicle-control intratumorally and
monitored for tumor growth and survival. IL-4-PE effec-
tively caused regression of tumors by 70% in all three
tumor models compared to vehicle control mice.
Responding animals showed complete regression of
tumors in 58% of mice at the highest dose in UM-UC-3
tumor model and 54% in SW780 tumor model. Overall, all
responding animals showed >8 week longer survival com-
pared to control mice. IL-4-PE immunotoxin at both
doses did not show any visible toxicity when administrated
intratumorally. Similar safety profile has been observed in
the clinic when IL-4-PE was administered intratumorally
in glioma trial [2]. Taken together our results demonstrate
that IL-4Ra in bladder cancer is a prognostic biomarker
and in addition it provides an excellent target for immu-
notherapy. Additional studies are ongoing to target
IL-4Ra with other immunotherapeutic approaches such as
cancer vaccines and adoptive cell transfer immunotherapy.
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